luzindole has been researched along with Alzheimer Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alonso-Gil, S; Conde, S; López, MG; López-Iglesias, B; Morales-García, JA; Pérez, C; Pérez-Castillo, A; Rodríguez-Franco, MI; Romero, A; Villarroya, M | 1 |
| Yao, K; Zhao, YF; Zu, HB | 1 |
2 other study(ies) available for luzindole and Alzheimer Disease
| Article | Year |
|---|---|
New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Blood-Brain Barrier; Cell Line; Cholinesterase Inhibitors; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Melatonin; Neuroprotective Agents; Spectrometry, Mass, Electrospray Ionization | 2014 |
Melatonin receptor stimulation by agomelatine prevents Aβ-induced tau phosphorylation and oxidative damage in PC12 cells.
Topics: Acetamides; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antidepressive Agents; Cell Survival; Malondialdehyde; Oxidative Stress; PC12 Cells; Peptide Fragments; Phosphorylation; Rats; Receptors, Melatonin; tau Proteins; Tryptamines | 2019 |